Trial Profile
An investigator-initiated double-blind, parallel-group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes: the GOLMePsA study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Methotrexate
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms GOLMePsA
- 09 Jan 2024 Status changed from recruiting to completed.
- 17 Jun 2016 Planned End Date changed from 1 Jun 2017 to 1 Apr 2018.
- 04 Dec 2015 Accrual to date is 1% according to United Kingdom Clinical Research Network record.